Van Gelder Race
Transcript of Van Gelder Race
![Page 1: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/1.jpg)
RACE II
RAte Control Efficacy in Permanent Atrial Fibrillation
A Randomized Comparison of Lenient Rate Control versus Strict Rate Control Concerning Morbidity and
Mortality
Isabelle C Van Gelder, Hessel F Groenveld, Harry J Crijns, Jan G Tijssen,Hans H Hillege, Ype Tuininga, Marco Alings, Hans Bosker, Jan Cornel,
Raymond Tukkie, Otto Kamp, Dirk J Van Veldhuisen, Maarten P Van den Berg,on behalf of the RACE II Investigators
![Page 2: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/2.jpg)
Rates of complications and death were similar in patients treated with rate-control and rhythm-control therapy
Since then, rate control has become front-line therapy in the management of AF
The optimal level of heart-rate control during AF is unknown
AFFIRM, RACE
Wyse et al. New Engl J Med 2002Van Gelder et al. New Engl J Med 2002
![Page 3: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/3.jpg)
ACC/AHA/ESC 2006 Guidelines
Strict rate control
At rest: 60 - 80
During moderate exercise: 90-115
Fuster et al. Guidelines J Am Coll Cardiol 2006
![Page 4: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/4.jpg)
Strict rate control ?
Contra
Difficult to achieve
Adverse effects drugs
More frequent pacemaker implants
Higher costs
![Page 5: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/5.jpg)
Hypothesis
Lenient rate control is not inferior to
strict rate control in patients with
permanent AF in terms of
cardiovascular morbidity and mortality
![Page 6: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/6.jpg)
RACE II trial
Prospective, randomized, open trial with
blinded endpoint evaluation
Multicenter, noninferiority trial conducted in
The Netherlands
2-3 years follow-up
![Page 7: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/7.jpg)
Inclusion criteria
Permanent AF ≤ 12 months
Resting heart rate > 80 bpm
On oral anticoagulation
Age ≤ 80 years
![Page 8: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/8.jpg)
Exclusion criteria
Paroxysmal or transient AF Known contra-indications for either strict or
lenient rate control (e.g. previous adverse effects on rate control drugs)
Unstable heart failure Cardiac surgery < 3 months Stroke Current or foreseen PM/ ICD/ CRT Inability to walk or bike
![Page 9: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/9.jpg)
Patients were randomized to
Lenient rate control
Strict rate control
Treatment
![Page 10: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/10.jpg)
Permanent AF > 80 bpm
lenient strict
![Page 11: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/11.jpg)
Permanent AF > 80 bpm
lenient strict
HR < 110 bpm(12 lead ECG)
![Page 12: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/12.jpg)
Permanent AF > 80 bpm
lenient strict
HR < 110 bpm(12 lead ECG)
![Page 13: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/13.jpg)
Permanent AF > 80 bpm
lenient strict
HR < 110 bpm(12 lead ECG)
HR < 80 bpm (12 lead ECG)and
HR < 110 bpm (at 25% duration of maximal exercise time)
![Page 14: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/14.jpg)
Permanent AF > 80 bpm
lenient strict
HR < 110 bpm(12 lead ECG)
HR < 80 bpm (12 lead ECG)and
HR < 110 bpm (at 25% duration of maximal exercise time)
After achieving rate control target:
Holter for safety
![Page 15: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/15.jpg)
Patients were treated with negative
dromotropic drugs (i.e. beta-blockers, non-
dihydropyridine calcium-channel blockers and
digoxin, alone or in combination).
Dosages of drugs were increased or drugs
combined until the heart rate target or targets
were achieved.
Treatment
![Page 16: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/16.jpg)
Primary outcome (composite)
Cardiovascular mortality
Hospitalization for heart failure
Stroke, systemic emboli, major bleeding
Syncope, sustained VT, cardiac arrest
Life-threatening adverse effects of RC drugs
Pacemaker implantation for bradycardia
ICD implantation for ventricular arrhythmias
![Page 17: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/17.jpg)
Noninferiority boundary is 10% absolute difference*
Statistical hypothesesHo: Rlenient - Rstrict > 10% (inferiority)H1: Rlenient - Rstrict < 10% (non-inferiority)
The null hypothesis of inferiority will be rejected when the upper limit of the 2-sided 90%-confidence interval of the risk difference does not exceed 10%.
Statistical analysis
* Comparable to the noninferiority boundary in the first RACE trial
![Page 18: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/18.jpg)
Baseline characteristics
Lenient control Strict
control
n= 311 n=303
Age 69±8 67±9
Male 66% 65%
Duration AF
Total duration 16 (6-54) 20 (6-64)
months
Permanent AF 3 (1-6) 2 (1-5)
months
![Page 19: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/19.jpg)
Baseline characteristics
Lenient control Strict control
n= 311 n=303
Hypertension 64% 58%
CAD 22% 15%Valve disease 21% 20%COPD 12% 14%Diabetes mellitus 12% 11%Lone AF 2% 2%
![Page 20: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/20.jpg)
Baseline characteristics
Lenient control Strict
control
n= 311 n=303
CHADS2 score 1.4±1.0 1.4±1.2
0-1 57% 64%
2 30% 22%
3-6 13% 14%
![Page 21: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/21.jpg)
Rate control targets at end ofdose-adjustment phase
Lenient control Strict control
n= 311 n=303
Rate control target 98% 67%* Resting target 98% 75% Exercise target - 73%
Visits to achieve target 0.2±0.6 2.3±1.4* Median 0 2* Interquartile range 0-0 1-3
* P<0.001
![Page 22: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/22.jpg)
Lenient control Strict control
n= 311 n=303
None 10% 1%*
Beta-blocker alone 42% 20%*
Calcium blocker alone 6% 5%
Digoxin alone 7% 2%*
Beta-blocker + calciumblocker 4% 13%*
Beta-blocker + digoxin 19% 37%*
Calciumblocker + digoxin 6% 10%
Beta + calciumblocker + digoxin 1% 9%*
Rate control medication at end ofdose-adjustment phase
* P<0.01
30% 69%*
![Page 23: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/23.jpg)
Lenient control Strict control
n= 311 n=303
Beta-blocker (normalized to
metoprolol-equivalent doses) 120±78 162±85
mg*
Verapamil 166±60 217±97
mg*
Digoxin 0.19±0.8 0.21±0.8
mg
Rate control doses at end ofdose-adjustment phase
* P<0.001
![Page 24: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/24.jpg)
0 3 12 24 3650
60
70
80
90
100
110
*
**
*
Heart rate during study
*
* P<0.001
* *
*
No. At RiskLenient 311 311 302 291 237Strict 303 303 284 277 240
Lenient
Strict
months
Hea
rt r
ate
(bea
ts p
er m
inut
e)
![Page 25: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/25.jpg)
0
5
10
15
20
0 6 12 18 24 30 36
No. At RiskStrict 303 282 273 262 246 212 131Lenient 311 298 290 285 255 218 138
Lenient
StrictC
umul
ativ
e In
cide
nce
(%)
14.9%
12.9%
months
Cumulative incidence primary outcome
![Page 26: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/26.jpg)
Lenient control Strict control
3-y incidence 12.9% 14.9%
Risk difference -2.0%90%-CI (-7.6%, 3.5%)
Upper limit 10%
Inferiority hypothesis was rejected (p<0.001)
Primary outcome
![Page 27: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/27.jpg)
Components of primary outcome
Lenient control Strict control
n= 311 n=303
Primary outcome 12.9% 14.9%
CV mortality 2.9% 3.9%Heart failure 3.8% 4.1%Stroke 1.6% 3.9%Emboli 0.3% 0%Bleeding 5.3% 4.5%Adverse effects RC drugs 1.1% 0.7%Pacemaker 0.8% 1.4%Syncope 1.0% 1.0%ICD 0% 0.4%
![Page 28: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/28.jpg)
Components of primary outcome
Lenient control Strict control
n= 311 n=303
Primary outcome 12.9% 14.9%
Nonfatal 10.0% 11.0%
Fatal 2.9% 3.9%
Cardiac arrhythmic 1.0% 1.4%
Cardiac nonarrhythmic 0.3% 0.8%
Noncardiac vascular 1.7% 1.9%
![Page 29: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/29.jpg)
3-y incidence Lenient control Strict control
All patients 12.9% 14.9%
CHADS2 < 2 12.4% 9.6%*
CHADS2 ≥ 2 13.6% 25.0%**
Inferiority hypothesis rejected for both subgroups (*p=0.02 and **p<0.001)
Primary outcome
![Page 30: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/30.jpg)
Symptoms
0
20
40
60
80
100
120
palpitations
fatigue
dyspnea
Lenient Strict Lenient Strict
% S
ymp
tom
s
PalpitationsFatigueDyspnea
baseline
end of study
![Page 31: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/31.jpg)
The RACE II study shows that lenient rate control is not inferior to strict rate control
Lenient rate control is more convenient since fewer outpatient visits, fewer examinations, lower doses and less often combination of drugs are needed
Conclusions
![Page 32: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/32.jpg)
Lenient rate control may be adopted as first choice rate control strategy in patients with permanent atrial fibrillation
This applies for high and low risk patients
Clinical implications
![Page 33: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/33.jpg)
Van Gelder,Groenveld,Van Veldhuisen, Van den Berg University Medical Center Groningen
Janssen, Tukkie Kennemer Hospital HaarlemBendermacher, Olthof Elkerliek Hospital HelmondRobles de Medina Hospital Leyenburg The HagueKuijer, Zwart Hospital Bernhoven OssCrijns Maastricht University Medical CenterAlings Amphia Hospital BredaPost Hospital HengeloPeters, Van Stralen, Buys Hospital Gooi Noord BlaricumDaniëls Jeroen Bosch Hospital Den BoschTimmermans Medical Spectrum Twente EnschedeKuijper, Van Doorn Spaarne Hospital HoofddorpHoogslag Diaconessen Hospital MeppelDen Hartog Hospital Gelderse Vallei EdeVan Rugge Diaconessen Hospital LeidenDerksen, Bosker Rijnstate Hospital ArnhemHamraoui Tweesteden Hospital TilburgDe Milliano Hospital HilversumKamp VU Medical Center AmsterdamKragten Atrium Medical Center HeerlenLinssen Twenteborg Hospital AlmeloTuininga, Badings Deventer Hospital DeventerNierop St. Franciscus Hospital RotterdamGratama VieCurie Hospital VenloNio, Muys, Van den Berg IJsselland Hospital, Capelle aan de
IJsselThijssen Maxima Medical Center VeldhovenVan Dijkman Bronovo Hospital The HagueCornel Medical Center AlkmaarVan der Galiën St.Lucas Hospital WinschotenBoersma St.Antonius ospital NieuwegeinBronzwaer Zaans Medical Center De Heel
ZaandamSpanjaard Delfzicht Hospital DelfzijlBartels Martini Hospital Groningen
![Page 34: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/34.jpg)
Steering CommitteeIsabelle C Van GelderHarry JGM CrijnsJan GP TijssenHans L HillegeYpe S TuiningaA Marco AlingsHans A BoskerJan H CornelOtto KampDirk J Van VeldhuisenMaarten P Van den Berg
Thesis ofHessel F Groenveld
Data Safety and Monitoring BoardHein J WellensRichard N HauerArthur A Wilde
Adjudication CommitteeJan Van der Meer†
Gert J LuijckxJohan Brügemann
Trial Coordination CenterHans L HillegeJanneke A BergsmaMarco AssmannOlga Eriks-De VriesMyke Mol
![Page 35: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/35.jpg)
This article is now available on the
New England Journal of Medicine’s
website, NEJM.org
![Page 36: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/36.jpg)
![Page 37: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/37.jpg)
0 5 10 15 minutes 25% exercise duration
total exercise recovery
150
100
bpm
Heart rate moderate exercise
50
02 8
![Page 38: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/38.jpg)
0 5 10 15 minutes 25% exercise duration
total exercise recovery
150
100
bpm
Heart rate moderate exercise
50
0
Heart rate 95 bpm
2 8
![Page 39: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/39.jpg)
Symptoms
Lenient control Strict control
At baseline 56% 58%Palpitations 20% 27%Dyspnea 34% 37%Fatigue 28% 32%
At end of study 46% 46%Palpitations 11% 10%Dyspnea 30% 30%Fatigue 24% 23%
![Page 40: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/40.jpg)
Patients were seen
Every 2 weeks until the rate control target
was achieved
After 1, 2 and 3 years of follow-up
Follow up visits
![Page 41: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/41.jpg)
Primary outcome according to HRat end dose adjustment phase
Lenient control Strict
control
% (events/total pts)
Total group 12.9 (38/311) 14.9 (43/303)
Heart rate < 70 - (1/1) 20.4
(13/67)
Heart rate 70-80 20.0 (1/5) 11.7
(18/161)
Heart rate 81-90 15.0 (16/112) 10.7 (4/39)
Heart rate 91-100 9.1 (11/123) 5.6 (1/20)
Heart rate > 100 14.1(9/70) 46.4 (7/16)
![Page 42: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/42.jpg)
Lenient control Strict
control
% (events/total pts)
Total group 12.9 (38/311) 14.9 (43/303)
Heart rate < 70 - (1/1) 20.4
(13/67)
Heart rate 70-80 20.0 (1/5) 11.7
(18/161)
Heart rate 81-90 15.0 (16/112) 10.7 (4/39)
Heart rate 91-100 9.1 (11/123) 5.6 (1/20)
Heart rate > 100 14.1(9/70) 46.4 (7/16)
Heart rate d at end ofdose adjustment phase
![Page 43: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/43.jpg)
total exercise recovery
25% exercise duration
![Page 44: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/44.jpg)
Strict rate control ?
Pro lower incidence CHF fewer strokes fewer bleeding better survival fewer symptoms improved quality of life
Contra difficult to achieve adverse effects drugs pacemaker implants higher costs
![Page 45: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/45.jpg)
Stroke
Sudden onset of focal neurological deficit
consistent with occlusion major cerebral artery
Documented by CT or MR imaging
Categorized as ischemic, hemorrhagic or
indeterminate
![Page 46: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/46.jpg)
Major bleeding
Requiring hospitalization with reduction of
hemoglobin level of at least 20 mg/L
Requiring transfusion of at least 2 units
Symptomatic bleeding in critical area or organ
Fatal
![Page 47: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/47.jpg)
Severe adverse effects RC drugs
Digitalis intoxication
Conduction disturbances necessitating
hospitalization
![Page 48: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/48.jpg)
0
1
2
3
4
non cardiacvascular
cardiac nonarrhythmic
carciacarrhythmic
2.9%
3.9%
Lenient control
noncardiac vascularcardiac nonarrhythmiccardiac arrhythmic
Strict control
% E
nd
po
int
Cardiovascular death
tabel
![Page 49: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/49.jpg)
Nonfatal and fatal endpoints
0
5
10
15
nonfatal
fatal
12.9%
14.9%
fatal
nonfatal
Strict controlLenient control
% E
nd
po
int
![Page 50: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/50.jpg)
Nonfatal and fatal endpoints
0
2
4
6
8
10
12
nonfatal
fatal
5.1%
Lenient Strict Lenient Strict
nonfatalfatal
CHADS2 ≥ 2CHADS2 < 210.0%
4.5%
3.5%
% E
nd
po
int
![Page 51: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/51.jpg)
0 12 24 3650
60
70
80
90
100
110
**
**
* P<0.001
* *
months
Lenient
Strict
No. At RiskLenient 311 302 291 237Strict 303 284 277 240
He
art
ra
te (
be
ats
pe
r m
inu
te)
Heart rate during study
![Page 52: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/52.jpg)
total exercise recovery
0 5 10 15 minutes
25% exercise duration
0 0
200
150
100
50
bpm
![Page 53: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/53.jpg)
total exercise recovery
0 5 10 15 minutes
25% exercise duration
0 0
200
150
100
50
bpm
Heart rate 105 bpm
![Page 54: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/54.jpg)
0 5 10 15 20 minutes
25% exercise duration
total exercise recovery
200
150
100
50
0
bpm
Heart rate moderate exercise
133.25
![Page 55: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/55.jpg)
0 5 10 15 20 minutes
25% exercise duration
200
150
100
50
Heart rate 130 bpm
0
bpm
Heart rate moderate exercise
133.25
total exercise recovery
![Page 56: Van Gelder Race](https://reader031.fdocuments.us/reader031/viewer/2022020207/557c831ed8b42ab0788b4a31/html5/thumbnails/56.jpg)
Baseline characteristics
Lenient control Strict
control
n= 311 n=303
Echocardiograpy (mm)
Left atrial size 46±6 46±7
LV end-diastolic size 51±7 51±8
LV end-systolic size 36±8 36±9
LV ejection fraction 52±11 52±12